Clinical trial NCT02369406: Early Infant HIV Treatment in Botswana
Official title: BHP Early Infant Treatment Study: a Clinical Treatment Trial of HIV+ Infants in Botswana
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
PHASE3
Conditions: HIV
Pediatric AIDS
Keywords: Botswana
Immunology
Antiretroviral Therapy
Lead sponsor: Harvard School of Public Health (HSPH)
Sponsor class: OTHER
Collaborators: name: Ragon Institute of MGH, MIT and Harvard
name: Brigham and Women's Hospital
name: Botswana Harvard Health Partnership
name: University of California, San Diego
First posted: 2015-02-24
Enrollment: 67
Sex: ALL
Minimum age (years): 0
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The overall objective of this study is to determine whether very early antiretroviral treatment (ART) initiation in HIV-infected infants limits the seeding of viral reservoirs and maintains immune responses, potentially allowing future periods off ART.

Detailed description: HIV-1 infection during adulthood leads to a stable, long-lasting viral reservoir in CD4 T cells that persists despite suppressive antiretroviral therapy (ART), and is responsible for rapid viral rebound once treatment is stopped in most cases. In neonates, HIV-1 infection occurs at a time when the adaptive immune system is still in development, which may alter the establishment of a long-lasting viral reservoir and offer opportunities to reduce viral persistence through early antiretroviral treatment. Recently, scientific understanding of neonatal HIV infection has been challenged by the description of an infant who tested positive for HIV at birth, was treated with potent combination antiretroviral therapy (ART) within the first 30 hours of life, and achieved long-term remission of HIV infection when ART was stopped approximately 18 months later. Unfortunately, after 2 years off ART, rebound viremia occurred in this child, yet this case raises the provocative question of whether ART initiated within the first days of life for an antepartum infection, or in the first days/weeks of life for a peripartum infection, can prevent the seeding of a long-lasting reservoir of HIV infected cells in some infants (and therefore lead to long periods of HIV remission off ART).

Eligibility criteria: Inclusion Criteria (antepartum infection cohort):

1. Mother/guardian ≥18 years of age and able to provide informed consent
2. Gestational age at birth ≥35 weeks
3. Birth weight ≥2000 grams
4. Age is less than 7 days\*
5. HIV-infection identified by testing conducted within 96 hours after birth NOTE: HIV-infection is defined as DNA PCR positive on at least one specimen, with confirmation specimen either positive or pending\*\*
6. Ability to initiate ART within 7 days after birth
7. Eligible for ART through the Botswana government program
8. Ability to be followed in BHP clinic for up to 240 weeks from enrollment#
9. Blood samples collected and submitted for real-time safety lab evaluations; results may be pending at the time of entry.

   * At least half of infants in the antepartum cohort must be \< 3 days at enrollment, including 3 of the first 6 infants enrolled.

     * Participants will be offered extended follow-up for up to 576 weeks. However, willingness to participate in optional extended follow-up is not an inclusion criterion.

Inclusion Criteria (peripartum infection cohort):

1. Mother/guardian ≥18 years of age and able to provide informed consent
2. Age is greater than 4 days and less than 57 days
3. HIV-negative within 96 hours after birth NOTE: HIV-negative is defined as HIV-negative by DNA PCR on a single specimen or HIV-negative on 2 separate confirmatory specimens following a re-test of an HIV-positive sample
4. HIV-positive between 96 hours and 56 days after birth NOTE: DNA PCR positive on at least one specimen with confirmation specimen either positive or pending repeat draw or result\*\*
5. Ability to initiate ART at enrollment
6. Eligible for ART through the Botswana government program
7. Ability to be followed in BHP clinic for ART for up to 240 weeks after enrollment#
8. Blood samples collected and submitted for real-time safety lab evaluations (results may be pending at the time of entry).

   * An enrolled infant later determined to be HIV uninfected by confirmatory testing will end participation in the study and this enrollment will not be counted against the total number of enrollments planned.

     * Participants will be offered extended follow-up for up to 576 weeks. However, willingness to participate in optional extended follow-up is not an inclusion criterion.

Inclusion Criteria (control group):

1. Mother/guardian ≥18 years of age and able to provide informed consent
2. 24-36 months of age
3. HIV-infection documented within 365 days after birth
4. ART initiated within the following timeframe based on timing of HIV-infection diagnosis \> 30-365 days after birth if HIV-infection diagnosed within 96 hours after birth OR \> 57-365 days after birth if infant was HIV-negative based on testing performed within 96 hours after birth (or if unknown HIV status \< 96 hours from birth) and then found to be HIV-positive based on testing performed between 96 hours and 365 days after birth.
5. After 6 months of ART, no more than one HIV RNA measurement \> 400 copies/mL

Exclusion Criteria (for antepartum and peripartum infection cohort):

1. Hospitalization for life-threatening medical illness
2. Medical condition making it unlikely that the infant will survive to 96 weeks
3. If lab values are available prior to enrollment, the following Division of AIDS 2014 graded results, from samples collected within 7 days prior to entry without subsequent testing, will exclude an infant:

   * Grade ≥3 ALT
   * Grade ≥3 AST
   * Grade ≥4 hemoglobin

Note: Baseline lab values may not be available at the time of ART start. However, as soon as these values are available (occasionally within \<24 hours), they will be used to make rapid treatment decisions. Neonates with baseline Grade 4 hemoglobin will be called immediately to have ZDV discontinued if the value is confirmed. Neonates with baseline Grade 3 or 4 ALT or AST will be called immediately to stop either NVP or LPV/r if the value is confirmed. Neonates who remain on ART may remain on study. Neonates who discontinue all ART for pre-ART laboratory abnormalities will not be counted against total enrollments.

Exclusion Criteria (control group):

1) \< 85% reported adherence to prescribed doses or interruption of ART for more than 7 consecutive days since its initiation.

Primary outcomes:
measure: To determine the proportion of infants who have treatment-limiting adverse events within the first 14 days of treatment
timeFrame: 14 days
measure: To determine the proportion of infants who fail to achieve at least a 1.5 log10 copies/mL reduction in HIV-1 RNA by the 14th day of treatment
timeFrame: 14 days
measure: To determine the proportion of infants in the antepartum cohort with trough drug concentrations below defined therapeutic ranges at 7 and 14 days of treatment (trough concentrations will be evaluated for NVP, ZDV, 3TC)
timeFrame: 14 days
measure: To evaluate virologic and immunologic outcomes of very early ART in infancy
timeFrame: 84-96 weeks
Secondary outcomes:
measure: Number of participants with HIV-1 RNA levels <40 copies/mL
timeFrame: up to 576 weeks
measure: Number of participants with reservoir HIV-1 DNA (in copies/million peripheral blood mononuclear cells, PBMCs) below the level of detection for total virus
timeFrame: up to 576 weeks
measure: Median CD4 cell count (cells/mm3) and 95% confidence intervals among participants
timeFrame: up to 576 weeks
Other outcomes:
Locations:
city: Gaborone
country: Botswana
facility: Botswana Harvard HIV/AIDS Institute Partnership
Study officials:
affiliation: Harvard School of Public Health (HSPH)
name: Roger L Shapiro, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Brigham and Women's Hospital
name: Daniel R. Kuritzkes, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ragon Institute of MGH, MIT and Harvard
name: Mathias Lichterfeld, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hartana CA, Garcia-Broncano P, Rassadkina Y, Lian X, Jiang C, Einkauf KB, Maswabi K, Ajibola G, Moyo S, Mohammed T, Maphorisa C, Makhema J, Yuki Y, Martin M, Bennett K, Jean-Philippe P, Viard M, Hughes MD, Powis KM, Carrington M, Lockman S, Gao C, Yu XG, Kuritzkes DR, Shapiro R, Lichterfeld M. Immune correlates of HIV-1 reservoir cell decline in early-treated infants. Cell Rep. 2022 Jul 19;40(3):111126. doi: 10.1016/j.celrep.2022.111126.
citation: Ibrahim M, Maswabi K, Ajibola G, Moyo S, Hughes MD, Batlang O, Sakoi M, Auletta-Young C, Vaughan L, Lockman S, Jean-Philippe P, Yu X, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro RL. Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana. J Int AIDS Soc. 2018 May;21(5):e25111. doi: 10.1002/jia2.25111.
citation: Maswabi K, Ajibola G, Bennett K, Capparelli EV, Jean-Philippe P, Moyo S, Mohammed T, Batlang O, Sakoi M, Lockman S, Makhema J, Lichterfeld M, Kuritzkes DR, Hughes MD, Shapiro RL. Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clin Infect Dis. 2021 Feb 1;72(3):388-393. doi: 10.1093/cid/ciaa028.
citation: Garcia-Broncano P, Maddali S, Einkauf KB, Jiang C, Gao C, Chevalier J, Chowdhury FZ, Maswabi K, Ajibola G, Moyo S, Mohammed T, Ncube T, Makhema J, Jean-Philippe P, Yu XG, Powis KM, Lockman S, Kuritzkes DR, Shapiro R, Lichterfeld M. Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Sci Transl Med. 2019 Nov 27;11(520):eaax7350. doi: 10.1126/scitranslmed.aax7350.
citation: Ajibola G, Garcia-Broncano P, Maswabi K, Bennett K, Hughes MD, Moyo S, Mohammed T, Jean-Philippe P, Sakoi M, Batlang O, Lockman S, Makhema J, Kuritzkes DR, Lichterfeld M, Shapiro RL. Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clin Infect Dis. 2021 Aug 16;73(4):e997-e1003. doi: 10.1093/cid/ciab143.
citation: Mistry R, Wilke R, Challiss RA. Modulation of NMDA effects on agonist-stimulated phosphoinositide turnover by memantine in neonatal rat cerebral cortex. Br J Pharmacol. 1995 Feb;114(4):797-804. doi: 10.1111/j.1476-5381.1995.tb13275.x.
citation: Gribakin FG. [Peculiarities of transmission of the receptor signal in photoreceptors]. Zh Evol Biokhim Fiziol. 1981 Sep-Oct;17(5):498-502. Russian.
citation: Helbing C, Gallimore C, Atkinson BG. Characterization of a Rana catesbeiana hsp30 gene and its expression in the liver of this amphibian during both spontaneous and thyroid hormone-induced metamorphosis. Dev Genet. 1996;18(3):223-33. doi: 10.1002/(SICI)1520-6408(1996)18:33.0.CO;2-B.
citation: Ibrahim M, Moyo S, Mohammed T, Mupfumi L, Gaseitsiwe S, Maswabi K, Ajibola G, Gelman R, Batlang O, Sakoi M, Auletta-Young C, Makhema J, Lockman S, Shapiro RL. Brief Report: High Sensitivity and Specificity of the Cepheid Xpert HIV-1 Qualitative Point-of-Care Test Among Newborns in Botswana. J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):e128-e131. doi: 10.1097/QAI.0000000000001384.
citation: Hartana CA, Broncano PG, Maswabi K, Ajibola G, Moyo S, Mohammed T, Maphorisa C, Makhema J, Powis KM, Lockman S, Burbelo PD, Gao C, Yu XG, Kuritzkes DR, Shapiro R, Lichterfeld M. Immune Modulation of HIV-1 Reservoir Size in Early-Treated Neonates. J Infect Dis. 2023 Aug 11;228(3):281-286. doi: 10.1093/infdis/jiad173.
citation: Ajibola G, Maswabi K, Hughes MD, Bennett K, Pretorius-Holme M, Capparelli EV, Jean-Philippe P, Moyo S, Mohammed T, Batlang O, Sakoi M, Ricci L, Lockman S, Makhema J, Kuritzkes DR, Lichterfeld M, Shapiro RL. Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial. J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):393-398. doi: 10.1097/QAI.0000000000003147.
citation: Moraka NO, Garcia-Broncano P, Hu Z, Ajibola G, Bareng OT, Pretorius-Holme M, Maswabi K, Maphorisa C, Mohammed T, Gaseitsiwe S, VanZyl GU, Kuritzkes DR, Lichterfeld M, Moyo S, Shapiro RL. Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. AIDS. 2021 Dec 1;35(15):2413-2421. doi: 10.1097/QAD.0000000000003041.